权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Investigating the Impact of ABL Kinase Signaling on Epigenetic Reprogramming in Metastatic Triple Negative Breast Cancer

研究 ABL 激酶信号转导对转移性三阴性乳腺癌表观遗传重编程的影响

基本信息

批准号：
10384189
负责人：
Ashley Colemon
金额：
$ 4.49万
依托单位：
DUKE UNIVERSITY
依托单位国家：
美国
项目类别：
财政年份：
2022
资助国家：
美国
起止时间：
2022-05-01 至 2025-04-30
项目状态：
未结题

来源：
https://reporter.nih.gov/project-details/10384189
关键词：
ATAC-seq Address Antitumor Response Biological Assay Brain Breast Cancer Cell Breast Cancer Model Breast Cancer cell line Breast cancer metastasis CRISPR screen Cancer Etiology Cell Death Cell Line Cell Survival Cessation of life Chromatin Chromatin Remodeling Factor Clinical Trials Combined Modality Therapy Data Drug Targeting Enzymes Epigenetic Process Family Genetic Transcription Goals Growth Factor Receptors Hormones Human Impairment In Vitro Knowledge Lead Link Malignant Neoplasms Metastatic to Modification Molecular Mus Neoplasm Metastasis Pathway interactions Patients Pharmacotherapy Phenotype Phosphotransferases Protein Tyrosine Kinase Relapse Research Signal Transduction Site Therapeutic Woman base bone cancer cell efficacy testing epigenetic drug epigenome experience experimental study genetic regulatory protein improved in vivo inhibitor loss of function migration mouse model novel therapeutic intervention novel therapeutics response standard of care therapeutically effective transcriptome transcriptomics triple-negative invasive breast carcinoma tumor tumor progression tumor xenograft

项目摘要

Because of its highly metastatic potential and limited treatment options, triple-negative breast cancer (TNBC) remains a leading cause of cancer associated deaths in women. Recent studies have shown that distinct chromatin landscapes correspond to metastatic relapse. Our lab has shown that the Abelson (ABL) family of non-receptor tyrosine kinases promote metastasis of breast cancer cells through activation of downstream transcriptional changes. However, how these changes exist in the greater context of global chromatin dynamics has yet to be explored. My preliminary data suggest that simultaneously targeting the epigenome and the ABL kinase- regulated transcriptome might be a promising new therapeutic strategy for treating metastatic triple negative breast cancer. The overall hypothesis of the proposal is that inhibition of ABL kinases leads to distinct changes in the chromatin landscape that sensitizes TNBC cells to treatment with drugs targeting epigenetic regulatory proteins leading to TNBC cell death. The aims of the proposal are to elucidate the epigenetic landscape associated with ABL kinase signaling to promote metastatic progression, and to understand how these dynamic changes might be exploited to elicit therapeutic benefit in metastatic TNBC models. Approaches used to address these objectives will include CRISPR/Cas9 screens, ATAC-seq, and in vitro and in vivo drug treatment experiments using cell lines and mice respectively.

由于其高转移潜力和有限的治疗选择，三阴性乳腺癌癌症（TNBC）仍然是妇女癌症相关死亡的主要原因。最近的研究已经表明不同的染色质景观对应于转移性复发。我们的实验室显示Abelson（ABL）家族的非受体酪氨酸激酶促进肿瘤的转移，乳腺癌细胞通过激活下游转录变化。但如何这些变化存在于全球染色质动力学的更大背景下，尚待探索。我的初步数据表明同时针对表观基因组和ABL激酶- 调控转录组可能是一种有前途的治疗转移性肝癌的新策略。三阴性乳腺癌该提案的总体假设是，ABL的抑制激酶导致染色质景观的明显变化，使TNBC细胞对用靶向表观遗传调节蛋白的药物治疗导致TNBC细胞死亡。的该提案的目的是阐明与ABL激酶相关的表观遗传景观信号，以促进转移进展，并了解这些动态变化，可用于在转移性TNBC模型中引发治疗益处。方法用于解决这些目标将包括CRISPR/Cas9筛选，ATAC-seq，以及体外和体内分别使用细胞系和小鼠进行药物治疗实验。